Euthyroid Group

Euthyroid is a clinical-stage biopharmaceutical company focused on developing optimized hormone replacement therapies for patients with hypothyroidism. The company's lead candidate, ET01, is a fixed-dose combination of levothyroxine (T4) and liothyronine (T3) formulated to restore physiological thyroid hormone levels more effectively than standard T4 monotherapy. Euthyroid's mission is to address the significant unmet need among the subset of hypothyroid patients who continue to experience symptoms such as fatigue and cognitive impairment despite achieving biochemical euthyroidism. The company is a spin-off from the Erasmus University Medical Center in Rotterdam, leveraging decades of clinical expertise in thyroid metabolism. By providing a standardized and physiologically balanced treatment, Euthyroid aims to improve the quality of life for millions of patients worldwide.